Global CAR T Cell Therapy Market Overview
CAR-T (Chimeric antigen receptor T) cells therapy is emerging as a promising approach for treating blood cancer. It is recognized as a new transformative type of cancer treatment that uses the immune system to fight diseases. Increasing incidence of blood cancer, rising number of patients showing response failure to alternative therapies, and growing preference for targeted therapies are major factors driving the growth of the global CAR T Cell Therapy market. Cancer is a prominent cause of death worldwide. According to the World Health Organization, cancer accounted for nearly 10 million deaths in 2020. An estimated 1.24 million blood cancer cases occur yearly worldwide, accounting for approximately 6% of all cancer cases. There are three main types of blood cancers: leukemia, lymphoma, and multiple. Lymphoma accounted for a significant share, followed by leukemia and multiple. CAR T-cell therapy is also being studied in the treatment of other types of cancer. Rapid advances and growth of CAR T-cell therapy are exceeding the expectations.
Rising approvals by regulatory for research, strong efficacy data in clinical trials, and rapid expansion of investigative pipeline are expected to create ample opportunities in the global market. However, the availability of other alternative therapeutics and the threat of potential post side effects hamper the global market growth to a large extend. Chemotherapy and radiotherapy are primary for preference for treating any cancer disease. CAR T-cell therapy is yet to gain acceptance due to low probability of survival, low awareness, and shortage of specialists performing a treatment. CAR T-cell therapy also causes several problematic and sometimes fatal side effects. One of the most common is cytokine release syndrome (CRS) and B cells' mass die-off. Another severe and potentially fatal side effect noticed is swelling in the brain or cerebral edema.
Gilead Sciences Inc. (U.S.), Novartis AG (Switzerland), Bristol-Myers Squibb Company (U.S.), Johnson & Johnson Services Inc. (Janssen Global Services LLC) (U.S.), Caribou Biosciences Inc. (U.S.), CARsgenTherapeutics Co. Ltd (China), JW Therapeutics (Shanghai) Co. Ltd. (China), Cartesian Therapeutics Inc. (U.S.), Aurora Biopharma (U.S.) are key companies operating in the global CAR T Cell Therapy market. Key market companies are engaged in extensive research and development of new targeted cell therapies in the market. Moreover, key players adopt merger and acquisition strategies to pace the research activities and enhance share in the global CAR T Cell Therapy market.
In this research report, the global CAR T Cell Therapy market is segmented by target antigen, therapeutic application, and region.
Analysis, By Target Antigen
By target antigen, the global CAR T Cell Therapy market is divided into CD19, CD20, GD2, CD22, CD30, CD33, HER1, HER2, and others. CD19 grabbed 45% of the global CAR T Cell Therapy market by target antigen type due to a strong response rate. CD-19 specific CAR-T therapy has induced high initial response rates and a strong signal for efficacy in blood cancer patients. CD20 and CD30 are other prominent segments of the market. CD20 and CD30 are widely studied for their response towards curing conditions. They are considered potential targets by pharmaceutical companies and research organizations. Trials have been ongoing in this direction and showing success as well.
Analysis, By Therapeutic Application
By therapeutic application, the global CAR T Cell Therapy market is segmented into acute lymphocytic leukemia, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, acute myeloid leukemia, multiple myeloma, pancreatic cancer, neuroblasta, breast cancer, hepatocellular, carcinoma, colorectal cancer, and others. Among these, diffuse large B-cell lymphoma (DLBCL) accounted for the largest share. CAR T Cell Therapy is primarily used for treating blood cancer. Diffuse large B-cell lymphoma (DLBCL) is the most common type of blood cancer, representing 30% of all lymphoma cases. CAR T Cell Therapy has shown promising efficacy in patients with DLBCL.
Analysis, By Region
Based on region, the global CAR T Cell Therapy market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is dominating the global CAR T Cell Therapy market with a 40 % share. This is due to a rapid increase in cancer burden, the presence of many prominent players, the availability of skilled professionals, vital healthcare and medical research infrastructure, and rapid treatment by key players. Europe is the second-largest market for CAR T Cell Therapy. Asia Pacific region will grow with the emerging participation of companies in the CAR T Cell Therapy research and rising interest in adopting treatment on the patients.
Market Segmentation covered in the Report:
By Drug Type
By Indication
By End-user
By Region
1 . PREFACE
1.1. Report Description
1.1.1. Objective
1.1.2. Target Audience
1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3 . CAR T CELL THERAPY – INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter’s Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Drug Type
3.7.2 Market Attractiveness Analysis By Indication
3.7.3 Market Attractiveness Analysis By End-user
3.7.4 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1. List of Raw Materials
4.2.2. Raw Material Manufactures List
4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1. Direct Marketing
4.4.2. Indirect Marketing
4.4.3. Marketing Channel Development Trend
5 . GLOBAL CAR T CELL THERAPY MARKET ANALYSIS BY DRUG TYPE
5.1 Overview by Drug Type
5.2 Historical and Forecast Data
5.3 Analysis by Drug Type
5.4 Axicabtagene Ciloleucel (Yescarta) Historic and Forecast Sales by Regions
5.5 Brexucabtagene Autoleucel (Tecartus) Historic and Forecast Sales by Regions
5.6 Ciltacabtagene Autoleucel (Carvykti) Historic and Forecast Sales by Regions
5.7 Idecabtagene Vicleucel (Abecma) Historic and Forecast Sales by Regions
5.8 Lisocabtagene Maraleucel (Breyanzi) Historic and Forecast Sales by Regions
5.9 Tisagenlecleucel (Kymriah) Historic and Forecast Sales by Regions
5.10. Others Historic and Forecast Sales by Regions
6 . GLOBAL CAR T CELL THERAPY MARKET ANALYSIS BY INDICATION
...
Avail customized purchase options to meet your exact research needs: